Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis
- PMID: 17472989
- PMCID: PMC2111613
- DOI: 10.1136/ard.2006.062919
Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis
Abstract
Objectives: To find out whether autoantibodies to citrullinated telopeptides of type I and II collagens and to cyclic citrullinated peptides (CCPs) predict the development of rheumatoid arthritis (RA).
Methods: A case-control study (matched for sex, age and municipality) was nested within a Finnish cohort of 19072 adults who had neither arthritis nor a history of it at the baseline examination during 1973-7. 124 subjects developed RA by late 1989, and of these, 89 were positive for rheumatoid factor (RF). Preillness serum specimens were analysed for autoantibodies against arginine (A)- or citrulline (C)-containing synthetic telopeptides using a chemiluminescence method and for anti-CCPs Mark2 with an enzyme-linked immunosorbent assay method.
Results: The mean levels of autoantibodies to citrulline-containing telopeptides and the C/A ratios of type I and II collagens and to CCP were higher in subjects who later developed RF-positive RA. In the highest tertiles of C/A (I), C/A (II) ratios and anti-CCPs levels, the relative risk of RF-positive RA was significantly increased. In the multifactorial model, only anti-CCPs retained its statistical significance. However, the interaction term of C/A (II) ratio and anti-CCPs proved to be statistically significant (p = 0.02). The subjects ranked into the highest tertiles of both C/A (II) ratio and anti-CCPs had an odds ratio of 20.06 (95% confidence interval, 4.37 to 92.06) of developing RF-positive RA compared with those in the lowest tertiles of these antibodies. None of the autoantibodies predicted RF-negative RA.
Conclusion: Autoantibodies to citrullinated telopeptides of type I and II collagen and to CCPs exert a synergistic effect on the risk of seropositive RA.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Antibodies binding to citrullinated telopeptides of type I and type II collagens and to mutated citrullinated vimentin synergistically predict the development of seropositive rheumatoid arthritis.Ann Rheum Dis. 2012 Oct;71(10):1666-70. doi: 10.1136/annrheumdis-2011-200848. Epub 2012 Mar 14. Ann Rheum Dis. 2012. PMID: 22419777
-
Are there autoantibodies reacting against citrullinated peptides derived from type I and type II collagens in patients with rheumatoid arthritis?Ann Rheum Dis. 2005 Oct;64(10):1443-50. doi: 10.1136/ard.2004.031211. Ann Rheum Dis. 2005. PMID: 16162901 Free PMC article.
-
Inhibitory characteristics of citrullinated telopeptides of type I and II collagens for autoantibody binding in patients with rheumatoid arthritis.Rheumatology (Oxford). 2006 Nov;45(11):1364-9. doi: 10.1093/rheumatology/kel113. Epub 2006 Apr 21. Rheumatology (Oxford). 2006. PMID: 16632481
-
Anti-citrullinated protein antibodies and their clinical utility in rheumatoid arthritis.Int J Rheum Dis. 2013 Aug;16(4):379-86. doi: 10.1111/1756-185X.12129. Epub 2013 Jul 15. Int J Rheum Dis. 2013. PMID: 23992255 Review.
-
Clinical applications of autoimmunity to citrullinated proteins in rheumatoid arthritis, from improving diagnostics to future therapies.Recent Pat Inflamm Allergy Drug Discov. 2011 May;5(2):108-27. doi: 10.2174/187221311795399246. Recent Pat Inflamm Allergy Drug Discov. 2011. PMID: 21453269 Review.
Cited by
-
Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides.Arthritis Res Ther. 2015 Jan 9;17(1):2. doi: 10.1186/s13075-014-0515-z. Arthritis Res Ther. 2015. PMID: 25573503 Free PMC article.
-
Reactive oxygen species deficiency induces autoimmunity with type 1 interferon signature.Antioxid Redox Signal. 2014 Dec 1;21(16):2231-45. doi: 10.1089/ars.2013.5828. Epub 2014 Jul 29. Antioxid Redox Signal. 2014. PMID: 24787605 Free PMC article.
-
Different amounts of protein-bound citrulline and homocitrulline in foot joint tissues of a patient with anti-citrullinated protein antibody positive erosive rheumatoid arthritis.J Transl Med. 2013 Sep 23;11:224. doi: 10.1186/1479-5876-11-224. J Transl Med. 2013. PMID: 24060405 Free PMC article.
-
Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein/peptide antibodies that are associated with arthritis-related traits: studies of the etiology of rheumatoid arthritis.Arthritis Rheum. 2013 Aug;65(8):1995-2004. doi: 10.1002/art.38022. Arthritis Rheum. 2013. PMID: 23754702 Free PMC article.
-
Engineered T cells and their therapeutic applications in autoimmune diseases.Zool Res. 2022 Mar 18;43(2):150-165. doi: 10.24272/j.issn.2095-8137.2021.363. Zool Res. 2022. PMID: 35008131 Free PMC article. Review.
References
-
- Aho K, Heliövaara M. Risk factors for rheumatoid arthritis. Ann Med 200436242–251. - PubMed
-
- Nijenhuis S, Zendman A J W, Vossenaar E R, Pruijn G J M, van Venrooij W J. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA‐specific marker. Clin Chem Acta 200435017–34. - PubMed
-
- Yamada R, Suzuki A, Chang X, Yamamoto K. Citrullinated proteins in rheumatoid arthritis. Front Biosci 20051054–64. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical